USCAP 2020 | Introduction of The Aperio AT2 DX System Clinical Validation Study with Dr. Jinsong Qiu
Leica Biosystems is proud to present:
Validation of A Digital Pathology System for Primary Diagnosis in Surgical Pathology with Dr. Jinsong Qiu, PhD
Wednesday, March 4th, 2020
West Exhibit Hall A – Room #2
12:00 pm – 1:00 pm
The adoption of digital pathology for pathological primary diagnosis has significant potential to transform pathology practice. You will learn about how this study investigated the digital scanner system’s precision performance and evaluated its accuracy by comparing pathologists’ diagnoses derived from WSI versus the standard microscope on 2045 cases.
Dr. Jinsong Qiu is an expert in clinical trial design and management in the in vitro diagnostic (IVD), pharmaceutical, and medical device industries. Dr. Qiu joined Leica Biosystems in 2017,where he led the clinical validation studies for the Aperio AT2 DX digital imaging system, which gained FDA 510 (k) clearance in 2019.
Prior to Leica Biosystems, Dr. Qiu was engaged in clinical research and translational medicine research across the broad disease spectrum in
multiple Fortune 500 companies including: Beckman Coulter, Novartis, and Pfizer.
Source: Leica Biosystems
